baber/WOPTO huggingface dataset:
Patent ES-2365798-T1 (ES)
Title: Goma gelán genéticamente purificada.
Inventor: CLEARY JOSEPH
IPC: A23L29/269
Filed: 2005-06-20
Abstract: Un cultivo microbiológicamente puro de Sphingomonas elodea que es deficiente en arilsulfatasa y que comprende una deleción de todo parte de su gen de arilsulfatasa, una inserción en su gen de arilsulfatasa o una mutación inactivante en su gen de arilsulfatasa.
Patent ES-2124203-T1 (ES)
Inventor: LEY ARTHUR CHARLES
IPC: C12N15/10
Filed: 1992-02-28
Abstract: The present invention relates to non-naturally occurring proteins which inhibit human neutrophile elastase, which proteins comprise at least the core sequence of a Kunitz domain. Other aspects of the invention relate to pharmaceutical compositions comprising these proteins, and the use of these proteins or compositions for use in medicine, in particular for the preparation of medicaments for the treatment of disorders or diseases associated with excessive human neutrophile elastase activity.
Patent ES-2152197-T1 (ES)
Title: Plasticos destinados al uso en la construccion.
Inventor: VINCENT IRVIN G
IPC: B32B27/00
Filed: 1999-06-26
Abstract: Plásticos destinados al uso en la construcción, caracterizados porque se emplean materiales reciclados de todo tipo de desechos de plásticos mezclados, así comoplásticos de fabricación primaria (PE, PVC, PP, PS, ABS, etc.) como material de construcción universal en construcciones altas y subterráneas.
Patent CY-1108998-T1 (CY)
Title: Πρωτεϊνες που δεσμευονται με οστεοπροτεγερινη και υποδοχεις
Inventor: BOYLE WILLIAM J
IPC: A61K31/70
Filed: 2007-06-21
Abstract: Ένα πρωτότυπο πολυπεπτίδιο, πρωτεΐνη που δεσμεύεται με οστεοπροτεγερίνη, που εμπλέκεται σε ωρίμανση οστεοκλαστών, ταυτοποιήθηκε με βάση την συγγένεια του για οστεοπροτεγερίνη. Περιγράφονται επίσης αλληλουχίες νουκλεϊκών οξέων που κωδικοποιούν το πολυπεπτίδιο, ή θραύσμα, ανάλογο ή παράγωγο αυτού, φορείς και κύτταρα-ξενιστές για παραγωγή, μέθοδοι παρασκευής πρωτεΐνης που δεσμεύεται με οστεοπροτεγερίνη, και προσδιορισμοί δέσμευσης. Παρέχονται επίσης συνθέσεις και μέθοδοι για την θεραπευτική αγωγή ασθενειών οστών όπως οστεοπόρωση, απώλεια οστού λόγω αρθρίτιδας ή μετάστασης, υπερασβεστιαιμία, και νόσος Paget. Περιγράφονται επίσης υποδοχείς για πρωτεΐνες που δεσμεύονται με οστεοπροτεγερίνη. Οι υποδοχείς, και αγωνιστές και ανταγωνιστές αυτών, μπορούν να χρησιμοποιηθούν για θεραπευτική αγωγή ασθενειών οστών.
Patent CY-1107058-T1 (CY)
Title: Φυσικα φωσφολιπιδια θαλασσιας προελευσης που περιεχουν φλαβονοειδη και πολυακορεστα φωσφολιπιδια και χρησεις αυτων
Inventor: SAMPALIS FOTINI
IPC: A23J7/00
Filed: 2007-08-28
Abstract: Εκχύλισμα φωσφολιπιδίου από θαλάσσια ή υδάτινη βιομάζα η οποία έχει θεραπευτικές ιδιότητες. Το εκχύλισμα φωσφολιπιδίου αποτελείται από μια ποικιλία φωσφολιπιδίων, λιπαρό οξύ, μέταλλα και ένα νέο φλαβονοειδές.
Patent CY-1108572-T1 (CY)
Title: Φαρμακα για nοσους του αμφιβληστροειδους και του χορειοειδους χιτωνα που περιεχουν στερεοειδη ως δραστικο συστατικο
Inventor: TANO YASUO
IPC: A61P27/02
Filed: 2008-11-17
Abstract: Ένας στόχος της παρούσας εφεύρεσης είναι να παράσχει θεραπευτικούς παράγοντες για διαταραχές του αμφιβληστροειδούς και του χοριοειδούς που περιλαμβάνουν ένα στεροειδές ως ένα δραστικό συστατικό και που έχουν βελτιωμένες επιδράσεις και δοσολογικές μορφές για θεραπεία των διαταραχών του αμφιβληστροειδούς και του χοριοειδούς όπου το στεροειδές μπορεί να χορηγείται εύκολα. Η παρούσα εφεύρεση αφορά σε θεραπευτικούς παράγοντες για διαταραχές του αμφιβληστροειδούς και του χοριοειδούς που περιλαμβάνουν βηταμεθαζόνη ή υδροκορτιζόνη ως ένα δραστικό συστατικό και σε εγχύσεις κάτω από τον επιπεφυκότα που περιλαμβάνουν το στεροειδές ως ένα δραστικό συστατικό.
Patent CY-1108625-T1 (CY)
Inventor: AJANI MAURO
IPC: A61K47/12
Filed: 2008-12-08
Abstract: Pharmaceutical compositions suitable for the oral administration of parnaparin and/or its salts, particularly controlled-release oral pharmaceutical compositions for the treatment of inflammatory bowel diseases and related conditions, are disclosed.
Patent CY-1109209-T1 (CY)
Inventor: GIAMMONA GAETANO
IPC: A61K9/19
Filed: 2009-07-03
Abstract: Compositions with pH-dependent modified release are described, consisting of hydrogel matrices containing one or more active ingredients, in which said matrices are suitable for releasing said active ingredients in a prolonged manner in given sites of the body.
Patent CY-1110200-T1 (CY)
Inventor: GIANNESI FABIO
IPC: C07F9/6561
Filed: 2010-07-13
Abstract: Compounds of formula (I) <CHEM> wherein the groups are as defined in the description are disclosed. <??>The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.
Patent CY-1112150-T1 (CY)
Inventor: FABRE PIERRE
IPC: A61P17/06
Filed: 2011-12-05
Abstract: Composition comprises a combination of glycerol, Vaseline(RTM: Petroleum jelly) and liquid paraffin in the form an oil-in-water or water-in-oil emulsion, as active ingredient. An independent claim is included for the use of the Vaseline(RTM: Petroleum jelly) having a drop point of 51-57[deg] C to prepare the composition, or a spectrum in NMR spectroscopy at 500 MHz of a 13C comprising a peak at 24.55 ppm of which the relative area for a witness of tetramethylsilane of 1% is 4-8 for preparing the composition. ACTIVITY : Dermatological; Antiinflammatory; Antipsoriatic; Vulnerary. MECHANISM OF ACTION : Serine protease.
Patent CY-1113169-T1 (CY)
Title: Πιστοποιηση διαπιστευτηριων για κινητους χρηστες
Inventor: FISHMAN NEIL S
IPC: H04L29/08
Filed: 2012-10-03
Abstract: Μέθοδοι, συστήματα και προϊόντα προγραμμάτων υπολογιστών για την πιστοποίηση ενός κινητού πελάτη, ο οποίος μπορεί να διαθέτει ένα σύστημα εισαγωγής, το οποίο είναι βελτιστοποιημένο για αριθμητική εισαγωγή. Μία κινητή πύλη λαμβάνει διαπιστευτήρια πιστοποίησης από έναν κινητό πελάτη και χρησιμοποιεί ένα φίλτρο πιστοποίησης για να χαρτογραφεί τα διαπιστευτήρια πιστοποίησης, σύμφωνα με προκαθορισμένα κριτήρια. Το φίλτρο πιστοποίησης μπορεί να αλλάζει το όνομα πεδίου, το όνομα χρήστη ή και τα δύο. Στη συνέχεια τα χαρτογραφημένα διαπιστευτήρια πιστοποίησης στέλλονται σε ένα δίκτυο, το οποίο περιλαμβάνει τον εξυπηρετητή περιεχομένου, στον οποίο γίνεται πρόσβαση. Οποιαδήποτε προνόμια πρόσβασης, τα οποία χορηγούνται στον κινητό πελάτη, βασίζονται στα χαρτογραφημένα διαπιστευτήρια πιστοποίησης. Η κινητή πύλη μπορεί να διαμορφώνεται ώστε να αποδέχεται συνδέσεις μόνο από γνωστούς εξυπηρετητές. Κινητά διαπιστευτήρια πιστοποίησης μπορούν να διατηρούνται σε ένα ή σε περισσότερους τομείς, έχοντας πιθανώς μία σχέση εμπιστοσύνης, ή μπορούν να αποθηκεύονται σε μία βάση δεδομένων διαπιστευτηρίων, η οποία διοικείται ξεχωριστά.
Patent CY-1114356-T1 (CY)
Title: Αναστολεις του ιου της ηπατιτιδας c
Inventor: RANDOLPH JOHN T
IPC: C07D417/14
Filed: 2013-06-26
Abstract: Περιγράφονται ενώσεις αποτελεσματικές στην αναστολή της αντιγραφής του ιού της Ηπατίτιδας C ("ΗCV"). Η παρούσα εφεύρεση αναφέρεται επίσης σε διεργασίες δημιουργίας αυτών των ενώσεων, σε συνθέσεις περιλαμβάνουσες αυτές τις ενώσεις και σε μεθόδους χρήσεως αυτών των ενώσεων για την αγωγή της μολύνσεως από ΗCV.
Patent CY-1115965-T1 (CY)
Title: Απταμερη δεσμευσης του συμπληρωματος και παραγοντες εναντι toy c5 χρησιμα στην αγωγη εναντι οφθαλμικων διαταραχων
Inventor: EPSTEIN DAVID
IPC: C12N15/11
Filed: 2015-01-16
Abstract: Μέθοδοι αγωγής έναντι οφθαλμικών διαταραχών που διαμεσολαβούνται από το συμπλήρωμα και που ενέχουν χορήγηση παραγόντων οι οποίοι αναστέλλουν ένα συστατικό του συμπληρώματος ενός ατόμου προς αγωγή έναντι της οφθαλμικής διαταραχής όπου, σε μια επιλεγμένη υλοποίηση, ο αναφερθείς παράγοντας είναι ένα απταμερές έναντι του συμπληρώματος το οποίο, σε μία προτιμούμενη υλοποίηση, είναι ένα απταμερές έναντι του C5.
Patent CY-1118980-T1 (CY)
Title: Στερεες μορφες ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδιου
Inventor: HURTER PATRICIA
IPC: C07D215/56
Filed: 2017-05-05
Abstract: Η παρούσα εφεύρεση αφορά σε στερεάς κατάστασης μορφές του Ν-[2,4-δις(1,1-διμεθυλαιθυλ)-5-υδροξυφαινυλ]-1,4-διυδρο-4-οξοκινολινο-3-καρβοξαμιδίου (Ένωση 1), φαρμακευτικές συνθέσεις αυτού και μεθόδους με αυτό.
Patent CY-1122651-T1 (CY)
Title: Μεθοδοι και συνθεσεις για προσδιορισμο της αντιστασης εναντι θεραπειας υποδοχεα ανδρογονου
Inventor: JOSEPH JAMES DAVID
IPC: C12Q1/6886
Filed: 2020-01-14
Abstract: Στο κείμενο περιγράφονται τροποποιημένα πολυπεπτίδια υποδοχέα ανδρογόνου τα οποία είναι ανθεκτικά έναντι αναστολής από αναστολέα υποδοχέα ανδρογόνου. Στο κείμενο περιγράφονται συνθέσεις, συνδυασμοί, και κιτ που περιέχουν τα τροποποιημένα πολυπεπτίδια υποδοχέα ανδρογόνου και μέθοδοι χρήσης των τροποποιημένων πολυπεπτιδίων υποδοχέα ανδρογόνου. Επίσης περιγράφονται μέθοδοι χρήσης των τροποποιημένων πολυπεπτιδίων υποδοχέα ανδρογόνου ως παράγοντες εξέτασης διαλογής για την ταυτοποίηση και σχεδιασμό διαμορφωτών υποδοχέα ανδρογόνου τρίτης γενιάς. Επίσης περιγράφονται διαμορφωτές υποδοχέα ανδρογόνου τρίτης γενιάς οι οποίοι αναστέλλουν την ενεργότητα των τροποποιημένων πολυπεπτιδίων υποδοχέα ανδρογόνου. Επίσης περιγράφονται φαρμακευτικές συνθέσεις και φάρμακα τα οποία εμπεριέχουν τις ενώσεις που περιγράφονται στο κείμενο, καθώς και μέθοδοι χρήσης τέτοιων διαμορφωτών υποδοχέα ανδρογόνου, μόνων και σε συνδυασμό με άλλες ενώσεις, για την αγωγή παθήσεων ή καταστάσεων, ακόμη και καρκίνων, όπως ευνουχοάντοχων καρκίνων προστάτη, οι οποίες μεσολαβούνται ή εξαρτώνται από υποδοχείς ανδρογόνων.
Patent SI-1779862-T1 (SI)
Title: Erythropoietin in subpolycythemic doses for treating diabetes
Inventor: BAHLMANN FERDINAND HERMANN DR
IPC: A61K38/00
Filed: 2003-07-25
Abstract: Use of erythropoetin (EPO) and/or its derivatives for stimulating, in endothelial precursor cells (EPC), any of physiological mobilization; proliferation; differentiation to endothelial cells and/or migration, in the direction of an angiogenic or vasculogenic stimulus. Independent claims are also included for the following: (1) use of EPO and/or its derivatives for stimulating formation of endothelial cells (EC) and/or for vasculogenesis; (2) use of EPO to produce a transplantable EC product; (3) use of EPO for treating a tissue or organ transplant; (4) use of EPO for pretreatment of tissue or organ transplants; (5) use of EPO to prepare implantable or transplantable, cell-containing in vitro organ or tissue systems; (6) use of EPO for coating vascular prostheses or heart valves; and (7) pharmaceutical composition containing (a) EPO, its derivatives, analogs, modifications or muteins and (b) at least one of vascular endothelial growth factor, PIGF (not defined), granulocyte-macrophage colony-stimulating factor and/or a hydroxymethyl glutarate-CoA reductase inhibitor. ACTIVITY : Antilipemic; Antidiabetic; Antiinflammatory; Antiarteriosclerosis; Cardiant; Vasotropic; Antianginal; Gynecological; Hypotensive; Nephrotropic. No details of tests for any of these activities are given. MECHANISM OF ACTION : Treatment with EPO increases adhesion of EPC and stimulates formation of endothelial tissue and blood vessels.
Patent SI-2258847-T1 (SI)
Title: Futher novel forms of interfering RNA molecules
Inventor: GIESE KLAUS
IPC: C12N15/00
Filed: 2003-08-05
Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double- stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
Patent SI-1454548-T1 (SI)
Title: Waterproof shoe
Inventor: KEIDEL KARSTEN FRIEDRICH
IPC: A43B7/12
Filed: 2004-02-05
Abstract: A waterproof shoe has a sole with a lining in the upper foot section. The upper section has an inner sock that is waterproof but water vapor permeable. The sock (2) has longitudinal slit in the sole, terminating each side in a lip that extends through a matching slit in the shoe insole (4).
Patent TR-200003019-T1 (TR)
Title: İkameli 2-fenil-1-(3,4-dihidroksi-5-nitrofenil)-1-etanonlar, bunları ihtiva eden farmasötik bileşimler
Inventor: BENES JAN
IPC: A61P25/00
Filed: 1999-12-17
Abstract: Formül I'e uygun yeni terkipler bazi merkezi ve çevresel sinir sistemi bozukluklarinin tedavisinde, katekolaminlerin 0-metilasyonunun azaltilmasinin tedaviye yönelik bir fayda saglayabilecegi durumlarda son derece etkili farmasötik özelliklere sahiptirler. Bu hastaliklara örnek olarak Parkinson hastaligi, parkinsona ait bozukluklar, sindirim sistemi rahatsizliklari, ödem ve yüksek tansiyon verilebilir.
Patent TR-201009065-T1 (TR)
Title: Kömür dönüştürüm yöntemi ve buradaki uygulamasina yönelik araç.
Inventor: STEPANOV SERGEY GRIGORIEVICH
IPC: C10B39/00
Filed: 2008-06-02
Abstract: Bulus elektrik mühendisliği kömür dönüstürüm alanı ile, özellikle de, metalurji, enerji üretim endüstrisi ve diğer endüstriler için kömür ve yüksek ısıl katı yakıtına (kok kömürü) dayanarak termal enerji üretimi ile alakalıdır.Bulusun temeli baslangıçtaki ham madde olarak, 0-35 mm’#&lik parçacık ölçülü kömür kullanan kömür dönüstürüm yöntemidir ve kömür islemi basarılı sekilde akıskan yatağın iki bölmesinde gerçeklestirilir. ?lk bölmede termal oksitlesme hava akısında 650 - 800 °C’#&de gerçeklestirilir veikinci bölmede üretilmis kok kömürü su buharından veya soğutulmus baca gazıyla soğutulur. Yöntemin uygulanması aracı bir kaynatma kazanı olarak sonuçlandırılır ki burada kazan ocağı bir bariyerle ayrılan akıskan yatağın iki bölmesinden olusur, ilk bölmeye hava akısı sağlanır ve ikinci bölmeye su buharı veya soğutulmus baca gazı sağlanır.
Patent TR-201207202-T1 (TR)
Title: Kapısı üzerinde dekoratif bir panel içeren bir ankastre bulaşık makinası.
Inventor: DURMAZ MEHMET
IPC: A47L15/42
Filed: 2010-12-24
Abstract: Bu buluş, mobilyanın içine yerleştirilen bir gövde (2), gövde (2) içine erişilmesini sağlayan, yatay bir eksen etrafında dönerek hareket eden bir kapı (3), ve kapının (3) üzerine, alt kenarı kapının (3) alt kenarından taşacak şekilde kayabilir olarak takılan dekoratif bir panel (4), kapıyı (3) gövdeyle (2) dönebilir şekilde birleştiren bir menteşe (6) ve bir ucu menteşeye (6) diğer ucu gövdeye (2) bağlı olup kapının (3) yavaş açılmasını sağlayan bir yay (8) içeren bir ankastre bulaşık makinası (1) ile ilgilidir.
Patent DE-3688329-T2 (DE)
Inventor: ETSCORN FRANK T
IPC: A61M37/00
Filed: 1986-05-23
Granted: 1993-09-23
Abstract: Percutaneous adminstration of nicotine in a dose approximating the dose delivered by a variety of nicotine-containing products, such as cigarettes, cigars, snuff and chewing tobacco, is carried out using an occlusive pad. The nicotine delivered so as to mimic the pharmacological effects of nicotine provided by the conventional use of tobacco, and a therapeutic function is achieved by reducing or eliminating the need for the tobacco product. A suitable transdermal application pad (10) comprises a reservoir (14) for liquid nicotine base (16) to be affixed to the skin in a variety of places. Due to the high lipid solubility and resultant high skin permeability of nicotine, vehicles or solvents are not generally needed to enhance dermal absorption. <IMAGE>
Patent DE-3751677-T2 (DE)
Inventor: CLARK STEVEN
IPC: C12N15/27
Filed: 1987-07-13
Granted: 1996-08-08
Abstract: A novel family of primate IL-3-like polypeptides is provided via recombinant techniques.
Patent DE-3781732-T2 (DE)
Inventor: CARROL JOHN O
IPC: C12N9/28
Filed: 1987-07-08
Granted: 1993-03-25
Abstract: An enzyme product comprising a mixture of the  alpha -amylase from Bacillus licheniformis and the  alpha -amylase from Bacillus stearothermophilus, said mixture containing from l0-90% by activity of the Bacillus licheniformis enzyme. The amylase mixture is advantageously used for liquefaction of starch or starchy grains.
Patent DE-3851274-T2 (DE)
Inventor: BARLOW GEORGE
IPC: G06F11/10
Filed: 1988-01-07
Granted: 1995-05-18
Abstract: An address path which transfers addresses from a number of sources includes an incrementing circuit. The address includes a plurality of address bits and integrity bits. The address bits are applied to the incrementing circuit while the integrity bits are applied in parallel to a programmable logic device (PLD). While the address is being transferred or incremented as required, the PLD independently generates a number of transform bits defining a characteristic of the number of address bits predicted to change state. Thereafter, the transform bits are used to transform the address integrity bits for transfer with the incremented address. The incremented address, transform bits and integrity bits are logically combined for verifying that the address was transferred and/or incremented without error.
Patent DE-3856342-T2 (DE)
Inventor: MARUYAMA TAKASHI
IPC: G06F13/00
Filed: 1988-08-17
Granted: 2000-02-03
Abstract: A bus error ascribable to a bus master module (2) other than a central processing unit (CPU) (1) is set as a specified factor for an exception process. When the exception process is requested, the CPU (1) executes a corresponding service program for the exception process without executing a process for altering and setting mask bits, which would be executed for a normal interrupt request. Thus, the exception process request specific to the bus error is not undesirably refused by interrupt requests etc., being accepted before the bus error. Furthermore there is a reduction in the time which is expended before the start of the run of a service program corresponding to the bus error, with the result that the reliability of the process for the bus error attributed to the predetermined bus master module (2) other than the CPU (1) is enhanced.
Patent DE-3856378-T2 (DE)
Inventor: HINDLEY RICHARD MARK BEECHAM P
IPC: B01D/
Filed: 1988-08-26
Granted: 2000-05-11
Abstract: Compounds of formula (I): <CHEM> or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein: A<1> represents a substituted or unsubstituted aromatic heterocyclyl group; R<1> represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R<2> and R<3> each represent hydrogen, or R<2> and R<3> together represent a bond; A<2> represents a benzene ring having in total up to five substituents; and  n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.
Patent DE-3875521-T2 (DE)
Inventor: MARSDEN STEPHEN ANDREW
IPC: G02B6/44
Filed: 1988-04-27
Granted: 1993-03-11
Abstract: A surveillance system in which a cyclically varying signal is launched into a data carrying optical fibre (3). The signal is reflected from the far end of the fibre and the returning signal compared with the launched signal. A change in the phase difference between the launched and returning signal is indicative of a change in length of the fibre. A microprocessor (8) is used to discount environmentally induced changes caused by temperature or traffic vibration. Alternatively the cyclically varying signal may also be transmitted to the far end of the fibre in digital form and after conversion used as the reference for comparison at the far end.
Patent DE-3876459-T2 (DE)
Inventor: ASH KEVIN JOHN
IPC: G11C29/00
Filed: 1988-01-22
Granted: 1993-06-09
Abstract: A memory may contain a large number of bytes of data perhaps as many as 256 megabytes in a typical large memory structure. An error correcting code algorithm may be used to identify failing memory modules in a memory system. In a particular embodiment, a number of spares may be provided on each memory card allowing a predetermined number of defective array modules to be replaced in a storage word. With double bit correction provided by the error correcting code logic, a number of bits can be corrected on a card or a larger number of bits can be corrected on a card pair, where the larger number of bits is somewhat less than double the number of bits which can be corrected on a single card. The address test in accordance with the present invention then produces a pattern that will create a difference greater than that larger number of bits between the data stored in a storage location under test and any address that could be accessed by an address line failure. The method according to the present invention predicts the effect of an address line failure external to the array modules and internal to a card pair and then tests to see if a failure has occurred. The address test does not declare an address failure until a predetermined number of bit failures on a card is found. The test is valid for single and multiple address line failures. Since only one address bit is changed for each path through the test other failing address lines will not be detected until the path with those failing address bits are tested. Thus, even with multiple address line failure the two addresses that are stored to and fetched from are the only one address bit apart.
Patent DE-3885182-T2 (DE)
Inventor: BORSETH DONALD
IPC: C08F20/04
Filed: 1988-07-28
Granted: 1994-02-24
Abstract: A surfactant-modified polymer characterized in that it comprises a polycarboxylate backbone and at least 0.5 percent by weight nonionic surfactant chemically associated therewith, the surfactant-modified polymer being formed by the polymerization of a reactant compound selected from carboxylic acids, polycarboxylic acids and mixtures thereof in an aqueous media in the presence of a nonionic surfactant is disclosed.
Patent DE-3888093-T2 (DE)
Inventor: HONORE TAGE
IPC: C07D241/38
Filed: 1988-11-08
Granted: 1994-06-09
Abstract: Heterocyclic dihydroxyquinoxaline compounds having the formula <CHEM>  wherein R<1> is C1-12-alkyl, which may obtionally be substituted by hydroxy, formyl, carboxy, carboxylic esters, amides or amines, C3-8-cycloalkyl, aryl, aralkyl; and wherein R<6> is, hydrogen, halogen, CN, CF3, NO2, or OR min , wherein R min  is C1-4-alkyl and R<5>, R<7> and R<8> is hydrogen, provided R<6> is not CF3, OCH3, NO2, CL or Br when R<1> is CH3; or R<6> and R<7> independently are NO2, halogen, CN, CF3, or OR min , wherein R min  is C1-4-alkyl, and R<5> and R<8> are each hydrogen; or R<5> and R<6> together form a further fused aromatic ring, which may be substituted with halogen, NO2, CN, CF3 or OR min , wherein R min is C1-4-alkyl, and R<7> and R<8> independently are hydrogen, halogen, CN, CF3, NO2 or OR min  wherein R min  is C1-4-alkyl; or R<7> and R<8> together form a further fused aromatic ring, which may be substituted with halogen, NO2, CN, CF3 or OR min , wherein R min is C1-4-alkyl, and R<5> and R<6> independently are hydrogen, halogen, CN, CF3, NO2 or OR min , wherein R min  is C1-4-alkyl. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.
Patent DE-3889833-T2 (DE)
Inventor: CHU ALBERT E
IPC: G01N33/76
Filed: 1988-09-30
Granted: 1994-09-08
Abstract: An improved device and method for analyte assay in liquid samples, wherein a porous membrane (18) with an immobilized receptor which is capable of directly or indirectly binding to the analyte is separated from a body of absorbent material (24) capable of absorbing the liquid sample by a septum (20) capable of substantially separating the porous membrane (18) from the absorbent body (24) while substantially directing the flow of the liquid sample from the porous membrane (18) to the absorbent body (24).